阿卡波糖与伏格列波糖比较治疗2型糖尿病的系统评价

发布时间：2019-04-18 18:01

【摘要】：目的：采用系统评价的方法,确定阿卡波糖(acarbose)与伏格列波糖(voglibose)比较治疗2型糖尿病(type 2 diabetes mellitus,T2DM)的降糖效果及不良反应。方法：计算机检索Cochrane Library、PubMed、OVID、MEDLINE、 EMBASE、CBM、CNKI、VIP、万方等数据库,检索时间为建库至2014年8月；对相关杂志纸质版及会议文献进行手工检索。严格按照系统评价手册上建议的评价方法由两名人员对文献进行筛选、质量评价、数据提取。将提取到的相关数据用RevMan 5.2软件进行统计分析。结果：通过各种途径共获得605篇文献,通过文献筛选,最终共有10篇临床随机对照试验(randomized controlled trial, RCTs)纳入研究。Meta分析结果显示：两种药物在降低餐后2小时血糖(2h Postprandial blood glucose,2h PBG)[MD=-0.04,95%CI(-0.43,0.35)]、空腹血糖(Fasting blood glucose,FBG)[MD=-0.04,95%CI(-0.43,0.35)]、糖化血红蛋白(glycoylated hemoglobin,HbAlc) [MD=0.01,95%CI(-0.20,0.22)]、总胆固醇(Total cholesterol, TC)[MD=0.12,95%CI(-0.31,0.55)]及甘油三脂(Triglyceride,TG) [MD=-0.14,95%CI(-0.42,0.15)]方面差异均无统计学意义。与伏格列波糖比较,阿卡波糖的不良反应发生率更高[OR=0.29, 95%CI(0.17,0.51), P0.001]。结论：与伏格列波糖相比,阿卡波糖在控制2型糖尿病PBG、HbA1c、 FBG、TC和TG方面的效果相似。与伏格列波糖相比,阿卡波糖的胃肠道不良反应发生率更高。
[Abstract]:Aim: to determine the hypoglycemic effects and adverse reactions of acarbose (acarbose) and Voliglitose (voglibose) in the treatment of type 2 diabetes mellitus (type 2 diabetes mellitus,T2DM) by systematic evaluation. Methods: the database of Cochrane Library,PubMed,OVID,MEDLINE, EMBASE,CBM,CNKI,VIP, Wanfang was searched by computer from August 2014 to August 2014, and the paper edition and conference literature of related journals were searched by hand. In strict accordance with the evaluation method recommended in the system evaluation manual, the literature was screened, the quality was evaluated and the data were extracted by two personnel. The relevant data were analyzed by RevMan 5.2software. Results: a total of 605 articles were obtained through various approaches, and 10 clinical randomized controlled trials (randomized controlled trial,) were selected. RCTs) included in the study. Meta-analysis showed that the two drugs reduced 2 hour postprandial blood glucose (2 h Postprandial blood glucose,2h PBG) [MD=-0.04,95%CI (- 0.43, 0.35)] and fasting blood glucose (Fasting blood glucose,. FBG) [MD=-0.04,95%CI (- 0.43, 0.35)], glycosylated hemoglobin (glycoylated hemoglobin,HbAlc) [MD=0.01,95%CI (- 0.20, 0.22)], total cholesterol (Total cholesterol, There was no significant difference in TC) [MD=0.12,95%CI (- 0.31, 0.55)] and triglyceride (Triglyceride,TG) [MD=-0.14,95%CI (- 0.42, 0.15)]. The adverse reaction rate of acarbose was higher than that of fumiglitose [OR=0.29, 95%CI (0.17, 0.51), P0.001]. Conclusion: the effect of acarbose on the control of PBG,HbA1c, FBG,TC and TG in type 2 diabetes mellitus is similar to that of valoglitose. Acarbose had a higher incidence of gastrointestinal adverse reactions than valoglitose.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R587.1

【相似文献】